Advancing Investigational New Drugs (INDs) can be a complex process, especially for smaller companies. Listen to your free podcast now as Marcus Delatte, PhD, Vice President at Allucent and Harshini Neelakantan, Executive Director at Ridgeline Therapeutics discuss best practices and considerations for leveraging your pre-IND meeting and submitting a successful IND application. Listen now for insights into: • Current trends and challenges related to IND submissions • The purpose and benefits of pre-IND meetings with regulatory bodies • Indicators that should prompt companies to request a pre-IND meeting • The role of consultants in supporting sponsors in pre-IND meetings • Getting the most from your pre-IND meeting and tips for IND application success • How IND submissions will evolve in the future

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related